ВЫБОР АНТИКОАГУЛЯНТА У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ, ПОДВЕРГАЕМЫХ КАРДИОВЕРСИИ
Аннотация
Список литературы
1. Zoll PM, Paul MH, Linenthal AJ et al. The effects of external electric currents on the heart: control of cardiac rhythm and induction and termination of cardiac arrhythmias // Circulation. 1956; 14: 745-756.
2. Вишневский А.А, Цукерман Б.М., Смеловский С.И. // Клиническая медицина, 1959, № 8, С.26.
3. Lown B., Amarasingham R., Neuman J. New method for terminating cardiac arrhythmias: use of synchronized capacitor discharge. JAMA // 1962; 182: 548-555.
4. Paul M.H., Miller R.A. External electrical termination of supraventricular arrhythmias in congenital heart disease // Circulation. 1962; 25: 604-609.
5. Jensen J.B., Humphries J.O., Kouwenhoven W.B., Jude J.R. Electroshock for atrial flutter and atrial fibrillation: follow-up studies on 50 patients // JAMA. 1965; 194: 1181-1184.
6. Lown B., Perlroth M.G., Kaidbey S. et al. «Cardioversion» of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients // N Engl J Med. 1963; 269: 325-331
7. Resnekov L., McDonald L. Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion // Br Heart J. 1967; 29: 926-936
8. Rokseth R. Clinical considerations in quinidine therapy of chronic auricular fibrillation. A study of 200 unselected patients with follow-up // Acta Med Scand. 1963; 174: 171-178.
9. Morris, J.J. Jr., Kong, Y., North, W.C. et al. Experience with «Cardioversion» of atrial fibrillation and flutter // Am J Cardiol. 1964; 14: 94-100.
10. Weinberg D.M., Mancini J. Anticoagulation for cardioversion of atrial fibrillation // Am J Cardiol. 1989; 63: 745-746.
11. Arnold A.Z., Mick M.J., Mazurek R.P. et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter // J Am Coll Cardiol. 1992; 19: 851-855.
12. Steering and Publications committees of the ACUTE Study. Design of a clinical trial for the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE multicenter study) // Am J Cardiol. 1998; 81: 877-883.
13. Bjerkelund C.J., Orning O.M. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation // Am J Cardiol. 1969; 23: 208-216.
14. Roy D., Marchand E., Gagné P. et al. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation // Am Heart J. 1986; 112: 1039-1043.
15. Klein A.L., Grimm R.A., Murray R.D. et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation // N Engl J Med. 2001; 344: 1411-1420.
16. Moreyra E., Finkelhor R.S., Cebul R.D. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials // Am Heart J. 1995; 129: 71-75.
17. De Caterina R., Husted S., Wallentin L. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013; 110: 1087-1107.
18. Wilshire J., Smith A., Bohm A. et al. Routine unselected access to day case electrical cardioversion of persistent atrial fibrillation: anticoagulant preparation is the key factor // Scott Med J. 2004; 49: 26-29.
19. Weinberg D.M., Mancini J. Anticoagulation for cardioversion of atrial fibrillation // Am J Cardiol. 1989; 63: 745746.
20. Ruff C.T., Giugliano R.P., Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials //Lancet. 2014; 383: 955-962.
21. January C.T, Wann S.L., Alpert J.S et al. 2014 AHA/ ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society // Circulation. 2014; 130: e199-e267.
22. Camm A.J., Lip G.Y.H., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association // Eur Heart J, 2012; 33: 2719-2747.
23. Nagaracanti R., Ezekowitz M.D., Oldgren J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. An analysis of Patients Undergoing Cardiversion // Circulation 2011; 123: 131-136.
24. Flaker G., Lopes R.D., Al-Khatib S.M. et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) // J Am Coll Cardiol. 2014; 63: 1082-1087.
25. Piccini J.P., Stevens S.R., Lokhnygina Y., et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial // J Am Coll Cardiol. 2013; 61: 19982006.
26. Cappato R., Ezekowitz M.D., Klein A.L. et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation // Eur Heart J. 2014; 35: 3346-3355.
27. Heidbuchel H., Verhamme P., Alings А. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation // Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology 2015, 17 (10): 1467-507.
Рецензия
Для цитирования:
Аверков О.В. ВЫБОР АНТИКОАГУЛЯНТА У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ, ПОДВЕРГАЕМЫХ КАРДИОВЕРСИИ. Вестник аритмологии. 2015;(82):27-31.
For citation:
Averkov O.A. SELECTION OF ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING CARDIOVERSION. Journal of Arrhythmology. 2015;(82):27-31. (In Russ.)